Table 1.

Sensitivity (IC50, pERK suppression) of human CRC or PDAC cell lines independent of KRAS G12D driver mutation while KRAS WT tumor cells are resistant

Cell Line	KRAS Mutation Status	pERK Inhibition	MRTX1133 IC50	Cell Line	KRAS Mutation Status	pERK Inhibition	MRTX1133 IC50
LS513	KRAS G12D	39 nM	39 nM	CAPAN-1	KRAS G12V	1.25 μM	2.5-3.5 μM
SNU-C2B	KRAS G12D	612 nM	1.25 μM	CAPAN-2	KRAS G12V	612 nM	1.2-2 μM
HPAF-II	KRAS G12D	1.25 μM	1.77 μM	SW480	KRAS G12V	612 nM	2.79 μM
AsPC-1	KRAS G12D	1.2 μM	1.5-2.4 μM	SW620	KRAS G12V	1.25 μM	3.6 μM
PANC-1	KRAS G12D	2 μM	2.5 μM	HCT-116	KRAS G13D	780 nM	2 μM
CFPAC1	KRAS G12V	1.25 μM	2.5-4 μM	HT-29	KRAS WT	-	> 10 μM
				BXCP3